During the last session, CureVac N.V (NASDAQ:CVAC)’s traded shares were 0.3 million, with the beta value of the company hitting 2.58. At the end of the trading day, the stock’s price was $3.16, reflecting an intraday loss of -1.25% or -$0.04. The 52-week high for the CVAC share is $6.30, that puts it down -99.37 from that peak though still a striking 30.06% gain since the share price plummeted to a 52-week low of $2.21. The company’s market capitalization is $708.81M, and the average intraday trading volume over the past 10 days was 0.57 million shares, and the average trade volume was 496.35K shares over the past three months.
CureVac N.V (CVAC) received a consensus recommendation of Buy from analysts. That translates to a mean rating of 2.17. CVAC has a Sell rating from 0 analyst(s) out of 2 analysts who have looked at this stock. 0 analyst(s) recommend to Hold the stock while 0 suggest Overweight, and 2 recommend a Buy rating for it. 0 analyst(s) has rated the stock Underweight. Company’s earnings per share (EPS) for the current quarter are expected to be -0.12.
CureVac N.V (NASDAQ:CVAC) trade information
CureVac N.V (CVAC) registered a -1.25% downside in the last session and has traded in the green over the past 5 sessions. The stock plummet -1.25% in intraday trading to $3.16, hitting a weekly high. The stock’s 5-day price performance is 1.94%, and it has moved by 14.91% in 30 days. Based on these gigs, the overall price performance for the year is -40.26%. The short interest in CureVac N.V (NASDAQ:CVAC) is 4.21 million shares and it means that shorts have 7.37 day(s) to cover.
The consensus price target of analysts on Wall Street is $29, which implies an increase of 89.1% to the stock’s current value. The extremes of the forecast give a target low and a target high price of $21 and $37 respectively. As a result, CVAC is trading at a discount of -1070.89% off the target high and -564.56% off the low.
CureVac N.V (CVAC) estimates and forecasts
Statistics show that CureVac N.V has outperformed its competitors in share price, compared to the industry in which it operates. CureVac N.V (CVAC) shares have gone down -13.90% during the last six months, with a year-to-date growth rate more than the industry average at 156.25% against 17.10. In the rating firms’ projections, revenue will increase 885.84% compared to the previous financial year.
As companies strive to predict their financial trajectories, we turn our attention to the forthcoming financial quarter. Here are the insights gathered from industry analysts. Revenue for the current quarter is expected to be 6.5M as predicted by 4 analyst(s). Meanwhile, a consensus of 2 analyst(s) estimates revenue growth to 13.56M by the end of current fiscal year. As per earnings report from last fiscal year’s results, sales for the corresponding quarters totaled 22.6M and 12.37M respectively. In this case, analysts expect current quarter sales to shrink by -71.24% and then jump by 9.57% in the coming quarter.
An analysis of the company’s performance over the past 5 years shows that the company’s earnings shrunk an estimated -23.15%. While earnings are projected to return 168.03% in 2024, the next five years will return -10.76% per annum.
CVAC Dividends
CureVac N.V is due to release its next quarterly earnings in January. However, it is important to remember that the dividend yield ratio is merely an indicator meant to only serve as guidance.
The next largest institutional holding, with 2.42 million shares, is of POINT72 ASSET MANAGEMENT, L.P.’s that is approximately 1.0802% of outstanding shares. At the market price on 2024-06-30, these shares were valued at $8.24 million.
